The pet care industry is having a moment, and pharmaceutical companies are racing to develop innovative treatments for companion animals. Elanco Animal Health Incorporated (ELAN) is emerging as a key player in this space, and KeyBanc Capital Markets thinks Wall Street is missing the story.
KeyBanc initiated coverage on the animal health company with an Overweight rating and a $27 price target on Thursday, arguing that shares are undervalued despite recent momentum. Analyst Steve Decher pointed to the company's recent Innovation Products launches, particularly Zenrelia and Credelio Quattro, which are showing strong revenue growth.
Here's the interesting part: Decher expects these Innovation Products to accelerate Elanco's top-line growth significantly over the next few years. He's forecasting 6-8% annual revenue growth from 2025 through 2028, compared to low single-digit growth from 2022 to 2024. That's a meaningful inflection point.
Margins and Balance Sheet Tell a Better Story
Beyond the revenue acceleration, KeyBanc sees margin expansion on the horizon. A higher revenue mix from Companion Animal products combined with ongoing cost savings initiatives should help profitability, according to the analyst.
The balance sheet picture has also improved dramatically. Elanco's trailing leverage ratio has dropped from approximately 5.5x in 2023 to around 4x currently. KeyBanc expects further deleveraging as the company generates more cash and profits improve.
Why the Premium Multiple Makes Sense
Elanco shares currently trade at roughly 21x forward earnings, which represents a premium to the company's two-year average of about 15.5x. On the surface, that might look expensive. But KeyBanc argues the higher multiple is justified given the company's improved growth trajectory, expanding margins, and stronger balance sheet.
The timing of KeyBanc's initiation is notable. Elanco reported third-quarter 2025 results on Wednesday that blew past expectations. The company posted adjusted earnings per share of 19 cents, up 46% year over year, crushing both its own guidance range of 12-16 cents and the consensus estimate of 13 cents.
Revenue came in at $1.14 billion, beating the consensus estimate of $1.09 billion and exceeding management's guidance range of $1.08 billion to $1.11 billion. Those are the kind of results that get analysts excited about a company's momentum.
Shares were up 3.84% at $22.05 on Friday, approaching the stock's 52-week high of $23.09. With KeyBanc's $27 price target, there's still meaningful upside from current levels if the firm's thesis plays out.
